Skip to main content
Clinical Trials/NCT01081561
NCT01081561
Unknown
Phase 2

Randomized Study of Corneal Collagen Cross-Linking With the UV-X System for the Treatment of Keratectasia in Eyes With Intacs Compared to Eyes Without Intacs

Yaron S. Rabinowitz M.D.1 site in 1 country600 target enrollmentJanuary 21, 2009
InterventionsRiboflavin

Overview

Phase
Phase 2
Intervention
Riboflavin
Conditions
Keratoconus
Sponsor
Yaron S. Rabinowitz M.D.
Enrollment
600
Locations
1
Primary Endpoint
Effectiveness of UV-X cross linking to halt progression of keratoconus
Last Updated
7 years ago

Overview

Brief Summary

This study will determine the efficacy of collagen cross linking for progressive keratoconus and ectasia after lasik. It will try and determine which is a more effective treatment: collagen cross linking alone or collagen cross linking combined with Intacs, a treatment which has already been proven to be effective in decreasing corneal curvature in patients with keratoconus.

Detailed Description

In this study we will attempt to determine whether Collagen Cross Linking alone, one combined with insertion of INTACS is the most effective treatment for patients with progressive keratoconus in patients who have progressive disease. These treatments have been widely used outside of the United States for the treatment of progressive keratoconus. Corneal Collagen Cross linking was recently approved in the United States for the treatment of progressive keratoconus. We will attempt to study 600 patients total. 300 patients will be assigned to cross linking only while another 300 will be assigned to cross linking and INTACS. Once adequate number of study subjects have been recruited data will be analyzed to determine which treatment is more effective. The following parameters from Topography, OCT and Tomography will be studied(these are Max K(pentacam) Kvalue(Tomey Topography)I-Svalue(Tomey Topography Astigmatism(Tomey Topography) and Min OCT(corneal pachymetry) any one of these metrics that achieve a value of 1 or more will be included in the analysis since the cornea is so irregular that values less than one could be artifact

Registry
clinicaltrials.gov
Start Date
January 21, 2009
End Date
June 30, 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Yaron S. Rabinowitz M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Yaron S. Rabinowitz M.D.

Yaron S Rabinowitz M.D.

Cornea Genetic Eye Institute

Eligibility Criteria

Inclusion Criteria

  • progressive keratoconus or ectasia

Exclusion Criteria

  • cornea thinner than 400um
  • K readings greater than 60D
  • Central corneal scarring

Arms & Interventions

Cross-linking

Corneal collagen cross-linking with riboflavin and UVA light

Intervention: Riboflavin

Cross-linking plus INTACS

Corneal collagen cross-linking with riboflavin and UVA light plus INTACS

Intervention: Riboflavin

Outcomes

Primary Outcomes

Effectiveness of UV-X cross linking to halt progression of keratoconus

Time Frame: 10 years

Any change of 1 or more of the following indices will be classified as progression. The following parameters will be studied Max K, Steep K, I-S value,Min OCT(pachymetry

Study Sites (1)

Loading locations...

Similar Trials